Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 513

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 513
---
 

    Shares issued for license 
     —  
     2,225,733 

    Gain on default judgement 
     (363,091) 
     — 

    Changes in operating assets and liabilities: 

    Accounts payable and accrued expenses 
     1,178,573  
     1,627,005 

    Accrued compensation 
     (282,856) 
     424,072 

    Due from Chromocell Corporation 
     (45,786) 
     — 

    Prepaid expenses 
     (65,300) 
     — 

    Deferred offering costs 
     (750,000) 
     — 

    Net Cash Used In Operating Activities 
     (5,792,483) 
     (981,031)

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Proceeds from loan payable, net of debt discount 
     536,184  
     201,008 

    Proceeds from loan payable - related party, net of debt discount 
     —  
     565,928 

    Payment of bridge loan, net of debt discount 
     (214,757) 
     — 

    Common stock issued for cash 
     5,972,000  
     255,412 

    Recission of common stock 
     (91,512) 
     — 

    Repurchase of Common Stock under Stock Repurchase Plan 
     (75,000) 
     — 

    Shares issued for cash under equity line of credit 
     82,620  
     — 

    Net Cash Provided By Financing Activities 
     6,209,535  
     1,022,348 

    NET INCREASE IN CASH 
     417,052  
     41,317 

    CASH AT BEGINNING OF YEAR 
     96,391  
     55,074 

    CASH AT END OF YEAR 
    $513,443  
    $96,391 

    Supplemental cash flow information: 

    Cash paid for income taxes 
    $—  
    $— 

    Cash paid for interest expense 
    $—  
    $— 

    NONCASH INVESTING AND FINANCING ACTIV